328 related articles for article (PubMed ID: 35893290)
1. Sex-Related Differences of Matrix Metalloproteinases (MMPs): New Perspectives for These Biomarkers in Cardiovascular and Neurological Diseases.
Trentini A; Manfrinato MC; Castellazzi M; Bellini T
J Pers Med; 2022 Jul; 12(8):. PubMed ID: 35893290
[TBL] [Abstract][Full Text] [Related]
2. Chemokines and matrix metalloproteinases in cerebrospinal fluid of patients with central nervous system complications caused by varicella-zoster virus.
Lind L; Eriksson K; Grahn A
J Neuroinflammation; 2019 Feb; 16(1):42. PubMed ID: 30777092
[TBL] [Abstract][Full Text] [Related]
3. Perspectives and New Aspects of Metalloproteinases' Inhibitors in the Therapy of CNS Disorders: From Chemistry to Medicine.
Boguszewska-Czubara A; Budzynska B; Skalicka-Wozniak K; Kurzepa J
Curr Med Chem; 2019; 26(18):3208-3224. PubMed ID: 29756562
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in the tumors of central nervous system (CNS).
Lukaszewicz-Zając M; Mroczko B; Kornhuber J; Lewczuk P
J Neural Transm (Vienna); 2014 May; 121(5):469-77. PubMed ID: 24366530
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinases as biomarkers of disease: updates and new insights.
Galliera E; Tacchini L; Corsi Romanelli MM
Clin Chem Lab Med; 2015 Feb; 53(3):349-55. PubMed ID: 25153404
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinases (MMPs) in health and disease: an overview.
Malemud CJ
Front Biosci; 2006 May; 11():1696-701. PubMed ID: 16368548
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of membrane type-matrix metalloproteinases in the inflamed or injured central nervous system.
Toft-Hansen H; Babcock AA; Millward JM; Owens T
J Neuroinflammation; 2007 Sep; 4():24. PubMed ID: 17883829
[TBL] [Abstract][Full Text] [Related]
8. Upregulated expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in BALB/c mouse brain challenged with Japanese encephalitis virus.
Shukla V; Kumar Shakya A; Dhole TN; Misra UK
Neuroimmunomodulation; 2012; 19(4):241-54. PubMed ID: 22441541
[TBL] [Abstract][Full Text] [Related]
9. Next generation matrix metalloproteinase inhibitors - Novel strategies bring new prospects.
Levin M; Udi Y; Solomonov I; Sagi I
Biochim Biophys Acta Mol Cell Res; 2017 Nov; 1864(11 Pt A):1927-1939. PubMed ID: 28636874
[TBL] [Abstract][Full Text] [Related]
10. Matrix Metalloproteinases (MMPs) in Targeted Drug Delivery: Synthesis of a Potent and Highly Selective Inhibitor against Matrix Metalloproteinase- 7.
Wang LL; Zhang B; Zheng MH; Xie YZ; Wang CJ; Jin JY
Curr Top Med Chem; 2020; 20(27):2459-2471. PubMed ID: 32703131
[TBL] [Abstract][Full Text] [Related]
11. Expression of matrix metalloproteinases in Naegleria fowleri and their role in invasion of the central nervous system.
Lam C; Jamerson M; Cabral G; Carlesso AM; Marciano-Cabral F
Microbiology (Reading); 2017 Oct; 163(10):1436-1444. PubMed ID: 28954644
[TBL] [Abstract][Full Text] [Related]
12. Selected Matrix Metalloproteinases (MMP-2, MMP-7) and Their Inhibitor (TIMP-2) in Adult and Pediatric Cancer.
Kaczorowska A; Miękus N; Stefanowicz J; Adamkiewicz-Drożyńska E
Diagnostics (Basel); 2020 Jul; 10(8):. PubMed ID: 32751899
[TBL] [Abstract][Full Text] [Related]
13. Biochemical and Biological Attributes of Matrix Metalloproteinases.
Cui N; Hu M; Khalil RA
Prog Mol Biol Transl Sci; 2017; 147():1-73. PubMed ID: 28413025
[TBL] [Abstract][Full Text] [Related]
14. Genetic variation of matrix metalloproteinase enzyme in HIV-associated neurocognitive disorder.
Singh H; Nain S; Krishnaraj A; Lata S; Dhole TN
Gene; 2019 May; 698():41-49. PubMed ID: 30825593
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinases and diseases of the central nervous system with a special emphasis on ischemic brain.
Gasche Y; Soccal PM; Kanemitsu M; Copin JC
Front Biosci; 2006 May; 11():1289-301. PubMed ID: 16368516
[TBL] [Abstract][Full Text] [Related]
16. The multifaceted role of metalloproteinases in physiological and pathological conditions in embryonic and adult brains.
De Stefano ME; Herrero MT
Prog Neurobiol; 2017 Aug; 155():36-56. PubMed ID: 27530222
[TBL] [Abstract][Full Text] [Related]
17. Circulating levels of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases during Japanese encephalitis virus infection.
Shukla V; Shakya AK; Shukla M; Kumari N; Krishnani N; Dhole TN; Misra UK
Virusdisease; 2016 Mar; 27(1):63-76. PubMed ID: 26925446
[TBL] [Abstract][Full Text] [Related]
18. Association of Plasma Matrix Metalloproteinase and Tissue Inhibitors of Matrix Metalloproteinase Levels With Adverse Treatment Outcomes Among Patients With Pulmonary Tuberculosis.
Kumar NP; Moideen K; Nancy A; Viswanathan V; Thiruvengadam K; Sivakumar S; Hissar S; Nair D; Banurekha VV; Kornfeld H; Babu S
JAMA Netw Open; 2020 Dec; 3(12):e2027754. PubMed ID: 33258908
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinases, new insights into the understanding of neurodegenerative disorders.
Kim YS; Joh TH
Biomol Ther (Seoul); 2012 Mar; 20(2):133-43. PubMed ID: 24116286
[TBL] [Abstract][Full Text] [Related]
20. Matrix Metalloproteinases in Pulmonary and Central Nervous System Tuberculosis-A Review.
Rohlwink UK; Walker NF; Ordonez AA; Li YJ; Tucker EW; Elkington PT; Wilkinson RJ; Wilkinson KA
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30889803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
